Ardelyx reports Q1 2026 results tonight — and the week's setup is more charged than the flat price action suggests.
Short sellers have been quietly adding throughout April, and options traders have shifted notably more defensive over the past two weeks.
Short interest has climbed roughly 16% over the past month to reach just over 11% of the free float, with around 24.9 million shares short as of Wednesday. That monthly build is the most consistent directional move in the borrow market since early Q1. The pace of accumulation accelerated through the second week of April — shares short jumped from roughly 21.4 million to nearly 24.6 million in a single week around April 9-10 — and has held near those elevated levels since. Availability in the lending pool remains very loose at around 1,577% of current short interest, meaning there is no shortage of supply for new shorts and no mechanical squeeze pressure at these levels. Cost to borrow is correspondingly cheap at 0.42%, down slightly on the week, though it has risen about 39% over the past month — a sign that incrementally more demand for borrows has been entering the market even if absolute rates remain modest.
Options positioning has turned more defensive. The put/call ratio is running at 0.38, nearly 1.8 standard deviations above its 20-day average of 0.31 — close to the most elevated reading of the past year, with the 52-week peak at 0.51. The shift is recent and sharp: as recently as mid-March, the PCR was below 0.20. That migration toward puts, alongside the short interest build, paints a picture of a trader base that is hedging into the print rather than leaning bullish.
The Street, however, remains firmly constructive. All recent analyst actions on record are Buy-equivalent ratings, with targets clustering between $14 and $19. The mean consensus target of $16.10 implies more than 160% upside to Wednesday's close of $6.01 — a gap that reflects the Street's view that the market has not yet priced in the full commercial trajectory of Ibsrela (IBS-C) and Xphozah (hyperphosphatemia in CKD). Bulls point to $265 million in cash at year-end 2025 as a solid runway, plus the potential label expansion of Ibsrela into chronic idiopathic constipation with enrollment expected to complete by year-end 2026 and a potential sNDA filing in late 2027. Bears counter that hitting revenue targets in both indications simultaneously requires execution in competitive, relatively small markets — and that rising SG&A investment to support the CIC push will pressure near-term margins. The EPS momentum factor score of 95 (30-day) is a genuine bright spot, suggesting estimates have been moving in the right direction recently, though the 90-day reading of 24 flags that the trend is newer than it looks.
The insider picture adds one notable data point. Independent Chairman David Mott bought 333,333 shares in late February at $5.84, a $1.95 million purchase that pushed his holding to roughly 3.26 million shares. That was a conviction-sized buy at a price close to where the stock trades now. CEO Mike Raab, by contrast, has been selling in small, regular increments — $261,000 in April, similar clips in March and February — consistent with a pre-planned disposition programme rather than a directional signal. State Street was a notable institutional buyer over the most recent reporting period, adding 2.19 million shares to reach 4.86% of shares outstanding.
Prior earnings have not been kind. The February 2026 print saw the stock fall nearly 15% in a single session, recovering only a fraction of that over the subsequent week. The Q4 2025 result delivered a more modest 2.4% single-day loss. The pattern is asymmetric — large downside on misses, limited recovery — which likely explains why options traders have been adding put coverage this week ahead of tonight's release. The 200-day moving average cross noted in recent coverage further underlines that the technical backdrop heading into tonight's print is fragile.
The read into tonight's result will be less about whether Ibsrela and Xphozah are growing and more about whether the growth rate, combined revenue guidance, and SG&A trajectory justify the chasm between where analysts have targets and where the stock is actually trading.
See the live data behind this article on ORTEX.
Open ARDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
